Otsuka to use IPO money to fund buyouts; Covagen closes Series A;

 @FierceBiotech: The Best of FierceBiotech 2010. Report | Follow @FierceBiotech

> Japan's Otsuka is reportedly telling investors that it will use the money raised from its IPO to fund the acquisition of drug businesses. Story

> Switzerland's Covagen says it closed a Series A financing round in which CHF 6.3 million was raised. Covagen release

Special Report: FierceBiotech's Top Writers in Biotech. Report

> Quintiles and London Genetics are teaming up on a new personalized medicines initiative. Quintiles release

> Merck says it is halting studies of a single dose of the HIV drug Isentress after pondering data demonstrating its inferiority to a twice-daily dose. Story

Special Report: The Top 10 Phase III Failures of 2010. Report

> Medicago announced an extension to its partnering agreement of July 2009 with Genopole. Medicago release

And Finally... By tweaking a gene, scientists say they were able to reverse the age-related decline of mice. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.